CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 90 enrolled
Drug / intervention
RFAprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03395379
NCT03395379N/ACompleted
CompareCT.gov

Air Dissection in Percutaneous Radiofrequency Ablation of T1a Renal Cell Carcinoma

Centre Hospitalier Universitaire de Nice·observational·Posted Jan 10, 2018·Updated Jan 10, 2018

In Brief

An observational study evaluating RFA for Unrecognized Condition. Completed, enrolled 90 participants.

Detailed Summary

The investigators aimed to evaluate the feasibility and safety of using ambient air to protect against thermal injury during RadioFrequency Ablation (RFA) for Renal Cell Carcinoma (RCC) based on data from cases at their institute.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsUnrecognized Condition
Countries--
CollaboratorsInstitut National de la Santé Et de la Recherche Médicale, France

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 10, 2018
Enrollment StartJan 11, 2012
Primary CompletionMar 15, 2016
Study CompletionMay 15, 2016
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 8.5 years ago

Interventions

RFAprocedure

Radiofrequency ablation (RFA) is a medical procedure in which part of the electrical conduction system of the tumor is ablated using the heat generated from medium frequency alternating current.